

What is the Cervix Cancer Research Network?

Objectives and Vision

January 28, 2017

David Gaffney MDPhd, FASTRO, FACR

**Steering Committee: Henry Kitchener, Sang Young Ryu, Bill Small,
Carlen Creutzberg, D. Thinh, Anuja Jhingran, Linda Mileskin,
A.Covens (IGCS) and Monica Bacon**

Cervix Cancer Research Network (CCRN)

- Research is difficult, but possible in cervix cancer
- Managed by the Gynecologic Cancer InterGroup
- Aim is to promote high quality clinical research from ***Non-GCIG sites!***
- ***More GCIG sites have substantial cervix cancer populations than several years ago***

Cervix cancer is a leading cause of death in women from Low “Development Index” countries, but not in High and Medium “Development Index” countries.

Atun et al. Expanding Global Access to Radiotherapy, Lancet Oncol. 16:1153-86, 2015


Why do we need the Cervix Cancer Research Network (CCRN)

- Too many women die from cervix cancer
- Too many women suffer from cervix cancer
- Research is difficult, but possible in cervix cancer

Cervix Cancer Research Network (CCRN)

- Managed by the Gynecologic Cancer InterGroup
- Aim is to promote high quality clinical research
- Literature search was performed to evaluate best practices
- Data input required (form developed by the Radiologic Physics Center, Houston, Tx)
- Participation in a beam measurement program (TLD/OSLD) is required every 2 yrs
- Site visits performed by an audit team from GCIG
- QA performed according to trial

GCIG: 27 Groups





7 groups in North America

14 groups in Europe

6 groups in Asia/Australia

GCIIG: Then and Now





CCRN: Goals of this Meeting

- Improve care and clinical research in cervix cancer
- Advance knowledge in cervix cancer therapy
- Support the on-going CCRN trials
- Develop new CCRN trials




FIGURE 1 | Workflow for CCRN site approval.

CCRN Trials

- TACO (KGOG/Thai)
- OUTBACK (ANZGOG)
- INTERLACE (NCRI)
- SHAPE (NCIC CTG)

> 60 accruals as of August 2015

CCRN Sites

Site	Trial	Auditors	Outcome
Tata India	OUTBACK	Narayan/Martyn	Approved Not activated
Bangalore India	OUTBACK	Narayan/Martyn	Approved Not activated
Lucknow India	OUTBACK	Narayan/Martyn	Not approved Action pending
Ramathibodi Thailand	TACO	Gaffney/Martyn	Approved Activated
Cluj Romania	INTERLACE	McCormick/Bacon	Pending (infrastructure)
Minsk Belarus	INTERLACE	McCormick/Bacon	Pending (infrastructure)
Trivandrum India	OUTBACK	Jhingran	Approved Not activated
Lahore Pakistan	OUTBACK	Narayan/Mirza	Pending
Siriraj Thailand	TACO	Small/Bacon/ Stonebraker	Approved*
Pramongkutklao Thailand	TACO	Stonebraker/ D.Kim	Approved
Ho Chi Ming Vietnam	TACO	Bacon/Stonebraker	Approved Activated

CCRN Sites

Location	Trial
Hertzen, Moscow	TACO/SHAPE
Russian Scientific Center of Roentgenoradiology, Moscow	TACO
Blokhin, Moscow	TACO
Zambia, Africa	Not approved -- in progress
Shanghia, China	TACO
Possible Future Sites	

CCRN: Significant Issues

- Money (Funding Sources)
 - IGCS (current support)
 - GCIG (current support)
 - Center for Global Health, NIH, USA
 - Gates Foundation and other foundations
 - Industry (Elekta/Varian/Pharma)
 - Burgeoning market
- Per case reimbursement?
- Accrual
- Ongoing oversight (QA and FU)
- Insurance/Indemnity issues
- Site Selection
- Infrastructure (clinical trials management)

CCRN: Summary

- 4 publically funded Cervix Cancer trials
- > 60 Accruals to date
- Site Selection is challenging
- Many willing expert volunteers
- Participation in cervix trials may improve care for regions and countries
- Very grateful for support from GCIg, IGCS, and Industry (Elekta, Varian, Zeria, Advaxis and Stendahl)

Survey Results: CCRN Participants

	Mean number	Range
# cervix cases/yr	255	6-1000
# rad oncs	5.3	2-15
# physicists	6.5	2-16
# dosimetrists	2.8	0-8
nurses	6.9	1-30
nurses' aides	3.4	0-10
% of patients getting chemoRT	85	60-100
% completing ≤ 8 weeks	84	60-100


Response rate of survey: 69%, 22/32.

Survey Results: CCRN Participants

	Yes (%)	No (%)	Other (%)
Labs available	100	0	
EQD2 conversion sheet used	64	27	9
2nd check of plan by physicist	59	36	5
Ultrasound used for tandem placement	32	41	27
Is uterus sounded	82	14	4
Smit sleeve used	5	86	9
Contrast placed in foley balloon	73	27	
Imaging and planning performed for each fraction	91	9	


Survey Results

Prescription




- Point A
- Volume
- Combination
- per case

Applicator



- T and O
- T and Cylinder
- Combination
- Interstitial

OAR Reporting



- Point
- Volume
- Both required